The CJC Ipamorelin nasal spray research format pairs a growth hormone-releasing hormone (GHRH) analog with a selective ghrelin receptor agonist in a single intranasal preparation, giving research groups a non-injectable delivery route to characterize in laboratory and preclinical models. This article examines how the intranasal blend is studied specifically as a delivery problem — how two peptides with different molecular weights and charge profiles behave at the nasal mucosa — rather than restating the receptor pharmacology covered elsewhere. It is written for investigators evaluating dosage-form and absorption questions in controlled research settings.
Research Use Only (RUO): All products and information referenced here are strictly for laboratory research use only. They are not for human or veterinary use, are not drugs or dietary supplements, and have not been evaluated by the FDA. Nothing here is intended to diagnose, treat, cure, or prevent any disease. No human or animal dosing protocol is provided or implied.
Why This Blend Is Studied as an Intranasal Format
CJC-1295 (without DAC) is a modified GHRH(1-29) fragment that binds the GHRH receptor on anterior pituitary somatotrophs, while Ipamorelin is a pentapeptide that selectively activates the growth hormone secretagogue receptor (GHS-R1a), the ghrelin receptor. In injectable research models, the two are frequently combined because they act on distinct but convergent pathways — one raising the amplitude of GH pulses via GHRH signaling, the other amplifying release through the ghrelin axis. The synergy between these two axes is explored in depth in GHRH + Ghrelin Synergy in GH Research, and the injectable blend itself is profiled in CJC-1295 no DAC + Ipamorelin Blend Research.
The intranasal format reframes that pharmacology as a formulation and transport question. Instead of asking what the receptors do, the research asks: can two peptides of this size and polarity cross the nasal epithelium in meaningful, reproducible fractions, and how does a spray-delivered preparation compare with a reconstituted injectable one? This is the specific angle that distinguishes a nasal-format study from a receptor study.
The Delivery Challenge: Two Peptides, Two Transport Profiles
Intranasal peptide absorption is governed by molecular weight, lipophilicity, charge, enzymatic stability at the mucosa, and residence time before mucociliary clearance. The general mechanism is detailed in Intranasal Peptide Delivery: Mechanism Guide; the practical point for this blend is that its two components do not behave identically.
| Property | CJC-1295 (no DAC) | Ipamorelin |
|---|---|---|
| Class | GHRH analog (peptide, ~30 aa) | Ghrelin mimetic (pentapeptide) |
| Approx. molecular weight | ~3,367 Da | ~711 Da |
| Receptor target | GHRH receptor | GHS-R1a |
| Nasal transport consideration | Larger; paracellular flux limited without permeation aids | Smaller; comparatively more permeable across mucosa |
Because Ipamorelin is roughly a fifth the mass of CJC-1295, research models generally treat the larger GHRH analog as the rate-limiting component for mucosal transport. Peptides above roughly 1 kDa cross the nasal epithelium poorly by passive diffusion, so studies of this format frequently focus on the transport ceiling of the CJC-1295 fraction and whether a co-formulated smaller peptide reaches the systemic compartment at a different fractional rate. This mismatch in bioavailability between the two components is a central variable investigators characterize.
Barriers Preclinical Models Examine
- Mucociliary clearance — the nasal cavity clears deposited material within minutes, capping the window for absorption.
- Enzymatic degradation — aminopeptidases and proteases at the mucosa can cleave peptides before uptake.
- Epithelial tight junctions — restrict paracellular passage of larger molecules such as the GHRH analog.
- Deposition pattern — spray droplet size and plume geometry determine where in the cavity the preparation lands, influencing contact with absorptive respiratory epithelium.
Formulation Variables in the Research Format
When laboratories study a spray-format blend, the dosage form itself becomes an independent variable. Common factors examined in intranasal peptide research include:
- Permeation enhancers — agents studied to transiently modulate tight junctions and raise transport of larger peptides.
- Enzyme-inhibition strategies — co-formulants investigated to slow mucosal peptide breakdown.
- Mucoadhesive vehicles — systems studied to extend residence time against clearance.
- pH and tonicity — parameters affecting peptide stability and epithelial compatibility in the preparation.
- Metered spray hardware — actuators that control deposited volume and droplet distribution for reproducible experiments.
A recurring theme is that the nasal format trades the near-complete bioavailability of an injection for convenience and a different absorption kinetic profile. That direct trade-off is the subject of Nasal Spray vs Reconstituted Peptide Formats, which compares the two delivery approaches used across peptide research. The same intranasal delivery questions apply to other molecules studied in spray form, such as the cofactor described in NAD+ Nasal Spray: Intranasal Research Format.
Laboratory Handling of the Preparation
The following are general laboratory handling considerations for peptide research preparations and are not use directions:
- Storage: Lyophilized research peptides are typically kept desiccated at -20 °C. Liquid or reconstituted nasal preparations are generally refrigerated at 2-8 °C and protected from light.
- Reconstitution: Bacteriostatic or sterile water is commonly used to prepare working solutions; gentle swirling rather than vigorous shaking is standard to limit peptide shear.
- Stability: Peptides in solution degrade faster than in lyophilized form, so aliquoting and defined study windows help preserve integrity.
- COA verification: Each NeuroLabs research item ships with third-party Certificate of Analysis documentation confirming ≥99% purity and identity by HPLC and mass spectrometry.
Featured Research Format
The CJC-1295 (without DAC) + Ipamorelin 5mg/5mg blend supplies both peptides in a matched research quantity suitable for formulation, in-vitro, and preclinical delivery studies. Every unit is COA-tested to ≥99% purity and ships same-day from the USA. For laboratory research use only.
For the broader landscape of spray-delivered research preparations — including format selection, absorption mechanisms, and handling — see the pillar guide, Peptide Nasal Spray Research Formats.
Frequently Asked Questions
What makes the intranasal CJC-1295/Ipamorelin format different to study versus the injectable?
The nasal format introduces mucosal transport as the limiting factor. Research shifts from receptor pharmacology to absorption kinetics, examining how much of each peptide crosses the nasal epithelium, how mucociliary clearance and enzymatic degradation reduce it, and how formulation aids modify those fractions.
Why are the two peptides expected to behave differently in the nasal cavity?
Ipamorelin (~711 Da) is far smaller than CJC-1295 without DAC (~3,367 Da). In preclinical models, smaller peptides generally cross the mucosa more readily, so the larger GHRH analog is often treated as the rate-limiting component and the two may reach the systemic compartment at different fractional rates.
Can this product be used intranasally by a person?
No. This is a research chemical for laboratory use only. It is not for human or veterinary use, is not FDA-approved, and no human dosing protocol is provided. All handling described is for in-vitro and preclinical research contexts.
How should the research preparation be stored?
Lyophilized peptide is typically stored desiccated at -20 °C, while reconstituted or liquid nasal preparations are generally refrigerated at 2-8 °C and protected from light. Aliquoting helps limit freeze-thaw and solution-phase degradation.
Does the blend ship with purity documentation?
Yes. Every NeuroLabs research peptide includes a third-party Certificate of Analysis confirming ≥99% purity and identity, with same-day USA shipping.